TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Stopped permanently closed per sponsor's request
Conditions
- Colorectal Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Breast Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Melanoma of the Skin
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Renal Cell Carcinoma
- Solid Neoplasm
- Stage IV Breast Cancer
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Colorectal Cancer
- Stage IVA Pancreatic Cancer
- Stage IVB Colorectal Cancer
- Stage IVB Pancreatic Cancer
Interventions
- DRUG: Cyclophosphamide
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pegfilgrastim
- OTHER: Pharmacological Study
- DRUG: TLR8 Agonist VTX-2337
Sponsor
Mayo Clinic
Collaborators